Network pharmacology, bioinformatics and in vitro/in vivo validation elucidate the anti-lung cancer activities and potential targets of Rhoifolin
Rhoifolin exerts potent and selective anti-lung cancer activity by directly targeting and downregulating EPHB2, providing a strong rationale for its further development as a novel therapeutic agent for lung cancer.
Authors
- Wei Cheng (ORCID: https://orcid.org/0000-0001-7686-775X)
- Yunhui Zhang (ORCID: https://orcid.org/0000-0002-6291-9448)
- Jing Qian (ORCID: https://orcid.org/0009-0008-2784-8147)
- Li Deng (ORCID: https://orcid.org/0000-0002-5639-4104)
- Di Gao
Institutions
- Qingdao University (CN)
- Southwest University (CN)
- First People's Hospital of Yunnan Province (CN)
- 81th Hospital of PLA (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-01-14
- DOI
- https://doi.org/10.3389/fphar.2025.1727729
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Kunming Medical University
- Ocean University of China
- Yunnan Provincial Science and Technology Department
- Applied Basic Research Foundation of Yunnan Province